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ABSTRACT 
Background. Mixed AdenoNeuroEndocrine Carcinomas (MANECs) of the gastrointestinal 
tract are rare neoplasms characterized by coexisting exocrine and neuroendocrine neoplastic 
components. MANECs' histogenetic classification and molecular characterization remain 
unclear, significantly affecting the identification of innovative therapeutic options for these 
tumors. Methods. In this study, the exocrine and neuroendocrine components of 6 
gastrointestinal MANECs were microdissected and subjected to the simultaneous mutation 
assessment in selected regions of 54 cancer-associated genes, using Ion Torrent 
semiconductor-based next-generation sequencing (NGS). Sanger sequencing and 
immunohistochemistry were used as validation of the mutational status. Results. A total of 
20 driver gene somatic mutations were observed among the 12 neoplastic components 
investigated. In 11 of 12 (91.7%) samples at least one mutation was detected; 7 samples 
(58.3%) were found to have multiple mutations. TP53 gene mutations were the most frequent 
genetic alterations observed in the series, occurring in 11/12 samples (91.7%). Somatic 
mutations in other genes were detected at lower frequencies: ATM, CTNNB1, ERBB4, JAK3, 
KDR, KRAS, RB1. Conclusions. Five of the six MANECs presented an overlapping 
mutational profile in both components, suggesting a monoclonal origin of the two MANEC 
components. 
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INTRODUCTION 
Mixed AdenoNeuroEndocrine Carcinomas (MANECs) of the gastrointestinal tract are rare 
and heterogeneous neoplasms characterized by coexisting exocrine and neuroendocrine 
neoplastic components [1,2]. According to WHO 2010 classification [3], either tumor 
component should represent at least 30% of the entire lesion. By the clinical point of view, 
MANECs are considered as carcinomas since both components are histologically malignant; 
tumor behavior is dictated by the most aggressive component, which is usually the 
neuroendocrine one [1,2]. 
 MANEC histogenetic definition represents a current controversial issue among 
pathologists [1,2,4-8]. Two main theories have been formulated: (i) these tumors might arise 
independently in a synchronous or methacronous fashion, or (ii) they might derive from a 
common, multipotent stem/progenitor cell. The presence in most MANECs of amphicrine 
cells characterized by the simultaneous presence of mucin droplets and neuroendocrine 
secretory granules strongly sustain the hypothesis of a common precursor cell capable of 
divergent differentiation [9,10]. This has also been supported by the majority of molecular 
studies, which suggested a possible multistep progression from a common precursor lesion, 
especially in those cases in which the neuroendocrine component is represented by a poorly 
differentiated carcinoma [1,7,11-13]. However, a comprehensive molecular characterization 
of these tumors is still lacking, and this significantly affects the introduction of innovative and 
targeted therapeutic options, which are currently left to subjective choices [1,14]. 
 Understanding the molecular basis of MANEC carcinogenesis and lineage 
commitment would be of fundamental importance in the prognostic and therapeutic 
stratification of these patients. To address this point, the exocrine and neuroendocrine 
components of 6 gastrointestinal MANECs were microdissected and subjected to the 
simultaneous mutational assessment in selected regions of 50 cancer-associated genes, 
using Ion Torrent semiconductor-based next-generation sequencing (NGS). The 
neuroendocrine components were also characterized by an AmpliSeq custom panel 
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MATERIALS AND METHODS 
Cases 
Six surgically-treated gastroenteropancreatic MANECs, (2 gastric, 2 pancreatic, 1 jejunal, 1 
rectal) were retrieved from the FFPE archives of the ARC-Net biobank at Verona University 
Hospital under the local ethics committee approval (n. prog. 1959).  
 
DNA extraction and qualification 
DNA was obtained from formalin-fixed paraffin-embedded (FFPE) tissues after enrichment 
for neoplastic cellularity. Suitable areas for microdissection were marked on archival 
haematoxylin and eosin (H&E) slides, which serve as templates. The corresponding tissue 
blocks were serially cut to 5-µm-thin sections. Unstained sections were therefore 
deparaffinized, and sligthly counterstained with haematoxylyn. Tumor cells were dissected 
manually using a sterile syringe needle, and at least 70% of neoplastic cells were collected 
from both exocrine and neuroendocrine components. Normal peritumoral tissues (i.e., non-
tumor gastrointestinal mucosa or pancreatic parenchyma) were microdissected and used to 
determine the somatic or germline nature of mutations. DNA was extracted using the 
QIAamp DNA FFPE Tissue Kit (Qiagen). DNA was quantified and its quality assessed using 
NanoDrop (Invitrogen) and Qubit (Invitrogen) platforms [15]. The quality of DNA was further 
evaluated by PCR using the BIOMED 2 PCR multiplex protocol [16]. 
 
Deep Sequencing of Multiplex PCR Amplicons 
Two multigene NGS panels were used: (1) the 50-gene Ion AmpliSeq Cancer Hotspot Panel 
v2 (Life Technologies) was tested on the two tumor components and the normal counterpart, 
(2) an Ampliseq neuroendocrine-custom panel investigating hotspots regions in MEN1, 
ATRX, DAXX, and TSC2 genes, which are frequently mutated in pancreatic neuroendocrine 
neoplasms [17-19], that was applied only on the neuroendocrine component of the MANEC 
and the normal sample. Details of the target regions for both panels are in Supplementary 
Tables 1 and 2. 
 The first panel explores selected regions of the following 50 genes: ABL1, AKT1, 
ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, 
FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, 
JAK2, JAK3, IDH2, KDR/VEGFR2, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, 
PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, 
TP53, VHL. 
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was performed with the OneTouch2 systems (Life Technologies). The quality of the obtained 
library was evaluated by the Agilent 2100 Bioanalyser on-chip electrophoresis (Agilent 
Technologies). Sequencing was run on the Ion Torrent Personal Genome Machine (PGM, 
Life Technologies) loaded with 316 (50-gene panel) or 318 chips (custom panel). Data 
analysis, including alignment to the hg19 human reference genome and variant calling, was 
done using the Torrent Suite Software v.3.2 and v.3.6 (Life Technologies). Filtered variants 
were annotated using the SnpEff software v.3.1 and the IonReporter software v.1.6 (Life 
Technologies). Alignments were visually verified with the Integrative Genomics Viewer; IGV 
v.2.2, Broad Institute. 
 
DNA Sanger Sequencing 
KRAS (exon 2) and TP53 (exons 5, 6, 7, 8) specific PCR fragments were analysed by 
Sanger sequencing. PCR products were purified using Agencourt AMPure XP magnetic 
beads (Beckman Coulter), labeled with Big Dye Terminator v3.1 (Applied Biosystems). 
Agencourt CleanSEQ magnetic beads (Beckman Coulter) were used for post-labeling 




The immunohistochemical expression of p53 (clone DO-1; prediluted; Immunotech) and ß-
catenin (clone 15B8; 1:150; Sigma) was tested as a surrogate validation of deep sequencing 
results, and performed as described elsewhere [20,21]. 
 
RESULTS 
Prevalence of driver genes mutations in gastrointestinal MANECs 
The clinico-pathological information of the six cases are summarized in Table 1. All patients 
were male, with a mean age of 72±10 years. Four tumors arose within the gastrointestinal 
tract (2 stomach, 1 jejunum, 1 rectum) and two were from the pancreas. All the exocrine 
components were represented by an adenocarcinoma; 5 cases were moderately 
differentiated, one was poorly differentiated. All the neuroendocrine components were poorly 
differentiated neuroendocrine carcinomas, characterized by a Ki67 index >20%. According to 
WHO 2010 classification, all morphologically and immunophenotypically-proven components 
represented at least 30% of the tumor. In all cases, collision (Figure 1A) and/or variably 
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 DNA from the microdissected components and from the adjacent normal tissue were 
subjected to deep sequencing of mutational hotspots of 54 genes. The mean read length 
was 101 base pairs and a mean coverage of 866x was achieved, with 96.8% target bases 
covered more than 100x by using the 50-genes hotspot Panel; the mean read length was 
108 base pairs and a mean coverage of 1,068x was achieved, with 75.4% target bases 
covered more than 100x by using the 4-genes neuroendocrine-custom panel. A minimum 
coverage of 20x was obtained in all samples for both panels. 
 A total of 20 somatic mutations were observed among the 50 cancer genes 
investigated by the Ion AmpliSeq Cancer Hotspot Panel v2. No mutation was observed 
among the custom panel-specific genes ATRX, DAXX, MEN1, and TSC2. 
 In 11 of 12 (91.7%) neoplastic samples - two components for each tumor - at least 
one somatic mutation was detected (Table 1); 7 samples (58.3%) showed multiple gene 
somatic mutations. 
 TP53 somatic mutations were the most frequent alterations observed in the series, 
occurring in all exocrine and 5/6 neuroendocrine components. Somatic mutations in other 
genes were detected at lower frequency: ATM, CTNNB1, ERBB4, JAK3, KDR, KRAS, RB1. 
 Most of the observed mutations were missense mutations. A stop mutation was 
observed in RB1 (R358*) and TP53 (R209Kfs*6); one deletion in ATM (S1923del) was found 
in the neuroendocrine component of a gastric MANEC (case #1). KRAS and TP53 gene 
mutations detected by deep sequencing were confirmed by PCR amplification of appropriate 
fragments and conventional Sanger sequencing. 
 
Mutation profile in matched MANEC components 
Five cases presented an overlapping mutational profile in both components (cases #1, #2, 
#3, #4, #5; Table 1, Figure 2). One of the pancreatic MANECs (case #6) presented no 
mutation in the 54 analyzed genes in the neuroendocrine component, while the exocrine 
component presented missense mutations in the CTNNB1 and TP53 genes (Figure 3). 
 Six mutations observed in the KRAS, RB1, and TP53 (n=4) genes were shared by 
both components of the same MANEC. Somatic point mutations in the CTNNB1 gene were 
found exclusively in exocrine components; somatic mutations in the ATM, ERBB4, JAK3, and 
KDR genes were found in neuroendocrine components. 
 B-catenin and p53 immunohistochemistry was used as a valid surrogate confirmation 
of the mutational status. As expected a nuclear/cytoplasmic ß-catenin immunoreaction was 


















   
   
   
   
   
   
   
   























  Neuroendocrinology (DOI:10.1159/000369071)  © 2014 S. Karger AG, Basel 7  
 
missense mutation in the CTNBB1 gene (Figure 2). This mutation has already been linked to 
the nuclear localization of the protein in desmoid tumors [22]. 
 Five of the six exocrine components and four of the five neuroendocrine components 
presenting TP53 somatic mutations showed a strong p53 nuclear immunostaining in more 
than 50% of neoplastic cells. In the negative case (case #4), the immunohistochemical 
negativity may be explained by the fact that the R209 stop mutation likely prevents p53 
stabilization, as reported for other similar mutations in TP53 [20]. An example of TP53 
mutational results from paired samples is shown in Figure 2. 
 
DISCUSSION 
The results of our mutational survey on a series of 6 routinely formalin-fixed paraffin-
embedded gastro-entero-pancreatic MANECs can be summarized as follows: (i) in most 
tumors, the two diverse components share similar molecular profiles, which supports an 
origin from a common progenitor cell of the tumor; (ii) the vast majority (91.7%) of neoplastic 
components harbor a driver-gene mutation; (iii) TP53 is a key gene in the carcinogenetic 
process of gastrointestinal MANECs; (iv) NGS of multiple genes is applicable to routinely-
processed tissues. 
 The concept of human cancers displaying a combination of exocrine (glandular or 
squamous; also urothelial in the genitourinary tract) and neuroendocrine features has been a 
matter of debate and still represents a controversial issue [1,3,5]. MANEC can present as 
composite neoplasms with exocrine and neuroendocrine components occurring in separate 
areas of the same lesion (i.e., collision tumor), or as combined neoplasms, when the two 
components are intimately and diffusely admixed [1]. Moreover, in amphicrine tumors 
exocrine and neuroendocrine features are present in the same neoplastic cell, which shows 
a double immunophenotype [1,3,5]. Thus, two main histogenetic theories have been 
proposed: the simultaneous proliferation of multiple cell lineages or the proliferation of 
stem/progenitor cells capable of differentiating along multiple cell lineages. 
 Most studies using different molecular techniques (i.e., loss of heterozygosity, 
mutational analysis, clonality analysis) claim that a common genetic origin of the two tumor 
components is more probable [1,7,11-13,23]. Shared LOH at various chromosomes suggest 
a multistep progression from a common precursor lesion, with a higher frequency of 
chromosomal abnormalities in the NEC than in the adenocarcinoma component [1]. 
 In our series, 5 of 6 cases presented similar mutational profiles in the two tumor 
components. Of interest, in cases #1 and #5 a common TP53 gene mutation coexisted with 
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ERBB4, ATM). This further supports the theory of a common precursor lesion that underwent 
divergent clonal evolution. Only case #6 showed a mutational profile compatible with the 
collision tumor theory, but it is also possible that the common ancestor mutation of this case 
is in a gene that is not included in the 54 genes explored herein. 
 Overall these histogenetic data are compatible with what is observed in clinical 
practice. A recent study on colorectal MANECs pinpointed that the type of cancer cell 
population in the metastatic site is largely unpredictable, being either mixed or pure [24]. 
Moreover, it did not necessarily correspond to the most prevalent or most aggressive 
neoplastic component [24]. By the prognostic point of view, it is generally considered that the 
clinical behavior of the tumor is dictated by the most aggressive component [1]. In the 
stomach, mixed tumors follow a behavior intermediate between pure large cell NEC, which is 
the most aggressive subgroup, and conventional gastric adenocarcinoma [25]. In the colon 
and rectum, the extent of the neuroendocrine component is not a predictor of behavior, and 
even a minor high-grade neuroendocrine cell population was found able to metastasize 
[24,26]. Very few cases of hepatobiliary MANEC have been reported so far and clinical 
comparisons are still missing [6]. 
 By deep sequencing 54 cancer-related genes, we observed that most neoplastic 
samples (11 of 12) presented at least one somatic mutation. TP53 gene mutations were the 
most frequent alterations observed in the series, and this was further confirmed by the strong 
p53 immunostaining observed in most samples. The presence of TP53, CTNBB1, KRAS, 
and RB1 alterations has already been observed in pancreatic NECs [27], supporting the 
aggressiveness of this tumor component. On the other hand, the lack of mutations in ATRX, 
DAXX, MEN1, and TSC2 supports a distinct molecular evolution of the NEC component from 
those reported for well-differentiated neuroendocrine tumors [28,29]. 
 As previously described for other tumor types [20,30,31], our results further support 
the clinical impact of targeted NGS on routinely processed samples. The integration of the 
mutational profiles with morphological and immunophenotypic data depicts a next-generation 
type of histopathological diagnosis. This approach allows both the description of cancer 
heterogeneity in a diagnostic report and the identification of potential therapeutic targets for 
which agents are currently in clinical trials. In this respect, our series showed mutations in 
genes that could have a clinical impact such as KRAS, ATM, JAK3, KDR/VEGFR2, and 
ERBB4. This information might represent the biological ground for planning future 
personalized target therapies in these patients. 
 In conclusion, the present NGS data are strongly suggestive to consider 
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approaches should investigate MANECs’ genomic landscape, which will improve the clinical 
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Figure 1. Representative histomorphological features of gastrointestinal MANECs. A 
tumor presenting areas in which the adenocarcinoma and neuroendocrine components are 
arranged as collision (A; H&E) or combined tumors (B; CD56 immunohistochemical staining 


















   
   
   
   
   
   
   
   



























Figure 2. MANEC exocrine and neuroendocrine components share similar mutational 
profiles. A jejunal MANEC showing a TP53 R248W mutation in both the exocine and 
neuroendocrine components. Representative p53 immunohistochemical images of the 
lesions are shown (original magnifications, 20x), and confirm that TP53 mutational status 
corresponds to p53 protein nuclear accumulation. On the right there is the representation of 
the reads aligned to the reference genome as provided by the Integrative Genomics Viewer 


















   
   
   
   
   
   
   
   























  Neuroendocrinology (DOI:10.1159/000369071)  © 2014 S. Karger AG, Basel 15  
 
 
Figure 3. Immunohistochemistry is a valid surrogate of ß-catenin and p53 mutational 
status. A pancreatic MANEC harboring a CTNNB1 and a TP53 mutation in the exocrine 
component that were absent in the neuroendocrine component. Representative ß-catenin 
and p53 immunohistochemical images of the exocrine lesion are shown (original 
magnifications, 20x). A nuclear and cytoplasmic ß-catenin immunoreaction and a p53 
nuclear accumulation were observed. The neuroendocrine component had a membranous ß-
catenin and a negative p53 immunostaining (not shown). On the right there is the 
corresponding representation of the gene sequence reads aligned to the reference genome 
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Table 1. Clinico-pathological features and mutational status of 6 gastroenteropancreatic 
MANECs 





















2 Male 80 Stomach G2/3 NEC G3 
(Ki67: 
72%) 
RB1 R358* (63%) 
TP53 R273C 
(63%) 
RB1 R358* (82%) 
TP53 R273C 
(77%) 














KRAS G13D (35%) 
TP53 R209Kfs*6 
(64%) 







KDR Q472H LOH 
JAK3 V722I LOH 
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